Vetter Pharma Plans State-of-the-Art €480M Production Facility in Germany
Introduction:
Vetter Pharma, a leading global pharmaceutical service provider specialising in injectable drugs, has announced plans to build a new state-of-the-art production facility in Saarlouis, Saarland, southwest Germany. The €480 million investment marks a key step in the company’s long-term global growth strategy.
Features:
The new facility will be located on a 95-acre industrial site strategically chosen for its regional advantages.
The plant is designed to significantly expand Vetter’s commercial production capacity, supporting the production of sterile injectable drugs to meet increasing global demand. The site is expected to create up to 2,000 jobs over the long term.
The European Commission has approved up to €47 million in state aid for the project, further supporting its development.
This investment complements Vetter’s ongoing expansion at other sites in Germany, Austria, and the United States, including a recently begun clinical production facility.
The facility will enhance Vetter’s ability to provide high-quality services and products during early clinical development and commercial production.
It reflects the company’s commitment to sustainable growth, innovation, and its role as a strategic partner in the global pharmaceutical market.
The new Saarlouis manufacturing site is expected to begin operations in 2031, significantly increasing Vetter Pharma’s production capacity and supporting its global expansion goals.
Specifications
| Name | Vetter Pharma |
| Budget | $480 Million |
| Type | Expansion |
| Year of Completion | 2031 |
